CA2105683C - N-¬¬4,5-dihydroxy-and 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl|carbonyl|amino acids useful in the therapy of osteoarticular affections - Google Patents
N-¬¬4,5-dihydroxy-and 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl|carbonyl|amino acids useful in the therapy of osteoarticular affections Download PDFInfo
- Publication number
- CA2105683C CA2105683C CA002105683A CA2105683A CA2105683C CA 2105683 C CA2105683 C CA 2105683C CA 002105683 A CA002105683 A CA 002105683A CA 2105683 A CA2105683 A CA 2105683A CA 2105683 C CA2105683 C CA 2105683C
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- dihydro
- dioxo
- osteoarticular
- affections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
N-[[4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl]carbonyl] amino acids having anti-inflammatory action, of general formula (1) wherein: X is selected from H and OH; R is a residue which, linked to the group a, forms an amino acid; a process for the preparation thereof and the use thereof in human therapy.
Description
N-[[4,5-DIHYDROXY- AND 4,5,8-TRIHYDROXY-9,10-DIHYDRO
9,10-DIOXO-2-ANTHRACENE-YL]CARBONYL]AMINO ACIDS USEFUL
IN THE THERAPY OF OSTEOARTICULAR AFFECTIONS
S The present invention relates to compounds of general formula ( I ) CO-NH-CH-R
X O
wherein:
X is selected from H and OH;
the group -NH-CH-R forms an amino acid residue; the COOH
enantiomers and racemic mixtures thereof; and the pharmaceutically acceptable salts thereof. Particularly preferred are those compounds in which the group -NH-IH-R
COOH
forms a natural amino acid residue. In particular, R is isobutyl, isopropyl, methylthioethyl. In formula I, the carbon atom substituted with the -NH-, -COOH, -R groups has absolute configuration (R).
The compounds of the invention derive from rhein, which has some therapeutical properties; particularly known is the antiarthrosic activity of diacerhein, which is the rhein diacetyl derivative or the 8-acetoxy derivative thereof.
9,10-DIOXO-2-ANTHRACENE-YL]CARBONYL]AMINO ACIDS USEFUL
IN THE THERAPY OF OSTEOARTICULAR AFFECTIONS
S The present invention relates to compounds of general formula ( I ) CO-NH-CH-R
X O
wherein:
X is selected from H and OH;
the group -NH-CH-R forms an amino acid residue; the COOH
enantiomers and racemic mixtures thereof; and the pharmaceutically acceptable salts thereof. Particularly preferred are those compounds in which the group -NH-IH-R
COOH
forms a natural amino acid residue. In particular, R is isobutyl, isopropyl, methylthioethyl. In formula I, the carbon atom substituted with the -NH-, -COOH, -R groups has absolute configuration (R).
The compounds of the invention derive from rhein, which has some therapeutical properties; particularly known is the antiarthrosic activity of diacerhein, which is the rhein diacetyl derivative or the 8-acetoxy derivative thereof.
The derivatives of rhein with natural amino acids, which are the object of the=_ present invention, proved to have interesting pharmacolog_Lcal activities which make them useful for the treatment of articular pathologies. In fact, preliminary pharmacological researches evidenced a marked inhibiting action c>n the elastase activity of human leukocytes, as well as an inhibiting activity on free radical form<~tion.
The compounds of' the invention are prepared according to conventional methods. Condensation of diacetylrhein with a compound of formula R-CH-COOK' , wherein Rl is a C1-C4 alkyl group, is carried out in anhydrous solvents such as methylene chloride, and in the presence of acid-binding agents, for example triethy=Lamine. The 4,5-hydroxy groups, and optionally the 8-hydroxv group, on the aromatic ring, and the carboxy group on the amino acidic portion are restored by means of h~Tdroly:~is of the corresponding esters .
An embodiment of the invention comprises the use of 2C diacetylrhein chloride.
The compounds of the invention can also be prepared by reacting 4,5-dicarbomethoxy-9,7.0-dihydro-9,10-dioxo-2 anthraceneca:rboxylic acid chloride with the compound of formula R-CH-COORl whE:~rein R1 is a Cl._C4 alkyl residue and the 2 ~~ NH2 ester groups are subsequently hydrolyzed.
The following examples further illustrate the invention.
2a EXA~2PLE
2-[[4,5-Dihdroxy-9,10-dihydro-9, 10-diaxo-2-anthracene-yl]carbonyl]amino-4-mett~l- pentanoic acid.
The compounds of' the invention are prepared according to conventional methods. Condensation of diacetylrhein with a compound of formula R-CH-COOK' , wherein Rl is a C1-C4 alkyl group, is carried out in anhydrous solvents such as methylene chloride, and in the presence of acid-binding agents, for example triethy=Lamine. The 4,5-hydroxy groups, and optionally the 8-hydroxv group, on the aromatic ring, and the carboxy group on the amino acidic portion are restored by means of h~Tdroly:~is of the corresponding esters .
An embodiment of the invention comprises the use of 2C diacetylrhein chloride.
The compounds of the invention can also be prepared by reacting 4,5-dicarbomethoxy-9,7.0-dihydro-9,10-dioxo-2 anthraceneca:rboxylic acid chloride with the compound of formula R-CH-COORl whE:~rein R1 is a Cl._C4 alkyl residue and the 2 ~~ NH2 ester groups are subsequently hydrolyzed.
The following examples further illustrate the invention.
2a EXA~2PLE
2-[[4,5-Dihdroxy-9,10-dihydro-9, 10-diaxo-2-anthracene-yl]carbonyl]amino-4-mett~l- pentanoic acid.
3.1 g (8 mmoles) of 4,5-~dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracenecarbo::ylic acid chloride are added under stirring to a solution of: dic:hloromethane (70 ml) containing 1.8 g (10 mmoles) of methyl 2-amino-4-methyl-pentanoate hydrochloride, 50 mg of p-N,N--dimethylamino-pyridine and 2.4 ml (16 mmoles) of triethy:lamine. The mixture is refluxed for 5 minutes, then i.t is left under stirring at room temperature fo:r a night..
The reaction is contro7_led by means of thin layer chromatography on silica gel plates, using as eluent diclorormethane-diethyl ether i.n a 10:1 ratio.
At the end of reaction, the reaction mixture is washed with water, the organic phase is separated ar.d solvent is evaporated off under reduced pressure and the residue is taken up into 5D ml of methanol and a solution of 5 g of potassium hydroxide in 50 ml of water, to obtain a purple solution. After about 30 minutes, the solution is acidified with 8% hydrochloric acid and filtered.
The precipitate is crystallized from an acetone-diethyl ether mixture, to obtain about 1.4 g of a product with m.p. - 204°-206°C
Elementary analysis for C21H19N0?
calculated % found %
C 63.47 63.40 H 4.81 4.7'7 N 3.52 3.56 I.R. in agreement 1H N.M.R, in agreement.
Analogously, the following compounds were prepared:
Ex. N. R Formula M.p.
2 (Cfi3)2CH- C20H1?NO? >210°C
3 CH3S(CH2)2- C20H17N0?S
The elementary analysis and the IR and 1H-NMR
spectra are .in agreefien t with the formulae and structures.
The compounds of the invention, due to the above mentioned ph~.rmacological properties thereof, can be WO 92/16496 ~ , PCT/EP92/00479 ~~.U~~~i~~
The reaction is contro7_led by means of thin layer chromatography on silica gel plates, using as eluent diclorormethane-diethyl ether i.n a 10:1 ratio.
At the end of reaction, the reaction mixture is washed with water, the organic phase is separated ar.d solvent is evaporated off under reduced pressure and the residue is taken up into 5D ml of methanol and a solution of 5 g of potassium hydroxide in 50 ml of water, to obtain a purple solution. After about 30 minutes, the solution is acidified with 8% hydrochloric acid and filtered.
The precipitate is crystallized from an acetone-diethyl ether mixture, to obtain about 1.4 g of a product with m.p. - 204°-206°C
Elementary analysis for C21H19N0?
calculated % found %
C 63.47 63.40 H 4.81 4.7'7 N 3.52 3.56 I.R. in agreement 1H N.M.R, in agreement.
Analogously, the following compounds were prepared:
Ex. N. R Formula M.p.
2 (Cfi3)2CH- C20H1?NO? >210°C
3 CH3S(CH2)2- C20H17N0?S
The elementary analysis and the IR and 1H-NMR
spectra are .in agreefien t with the formulae and structures.
The compounds of the invention, due to the above mentioned ph~.rmacological properties thereof, can be WO 92/16496 ~ , PCT/EP92/00479 ~~.U~~~i~~
used as active ingredients in pharmace~.itical forms prepared according to known techniques.
Examples of pharmaceutical forms are tablets, capsules, powders, syrups, injectable forms, suppositories.
The dosage unit will range from 5 to 500 mg of active ingredient per dose. The posology will depend on the severity of the disease to treat and the patient's conditions.
Examples of pharmaceutical forms are tablets, capsules, powders, syrups, injectable forms, suppositories.
The dosage unit will range from 5 to 500 mg of active ingredient per dose. The posology will depend on the severity of the disease to treat and the patient's conditions.
Claims (8)
1. Compounds of general formula (I) wherein:
X is selected from H and OH;
the group forms an amino acid residue; the enantiomers and racemic mixtures thereof; and the pharmaceutically acceptable salts thereof.
X is selected from H and OH;
the group forms an amino acid residue; the enantiomers and racemic mixtures thereof; and the pharmaceutically acceptable salts thereof.
2. Compounds of claim 1 wherein the group group forms a natural amino acid residue.
3. Compounds of claim 1 wherein R is isobutyl, isopropyl, methylthioethyl and wherein the carbon atom substituted with the -NH-, -COOH, -R groups has absolute configuration (R).
4. A process for the preparation of the compounds as defined in claims l, 2 and 3, characterized in that diacetylrhein or the 8-acetoxy derivative thereof are reacted with the compound of formula wherein R1 is C1-C4 alkyl residue and the ester groups are subsequently hydrolyzed.
5. A process for the preparation of the compounds as defined in claims 1, 2 and 3, characterized in that 4,5-dicarbomethoxy-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid chloride is reacted with the compound of formula wherein R1 is a C1-C4 aryl residue and the ester groups are subsequently hydrolyzed.
6. The use of the compounds as defined in claims 1, 2 and 3 as therapeutical agents.
7. Pharmaceutical compositions containing the compounds as defined in claims 1, 2 and 3 as the active ingredients in admixture with pharmaceutically acceptable carriers and excipients.
8. The use of compounds as defined in claims 1, 2 and 3 in the preparation of a medicament for the treatment of osteoarticular affections.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI91A000658 | 1991-03-12 | ||
| ITMI910658A IT1244773B (en) | 1991-03-12 | 1991-03-12 | N- (4,5-DIIDROSSI-E 4,5,8-TRIIDROSSI-9,10-DIIDRO-9,10-DIOSSO-2- ANTRACEN-IL) CARBONYL) AMINO ACIDS USABLE IN THE THERAPY OF OSTEOARTICULAR AFFECTIONS |
| PCT/EP1992/000479 WO1992016496A1 (en) | 1991-03-12 | 1992-03-04 | N-[[4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl]carbonyl]amino acids useful in the therapy of osteoarticular affections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2105683A1 CA2105683A1 (en) | 1992-09-13 |
| CA2105683C true CA2105683C (en) | 2003-09-16 |
Family
ID=11359001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002105683A Expired - Fee Related CA2105683C (en) | 1991-03-12 | 1992-03-04 | N-¬¬4,5-dihydroxy-and 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl|carbonyl|amino acids useful in the therapy of osteoarticular affections |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5451606A (en) |
| EP (1) | EP0588797B1 (en) |
| JP (1) | JP2979054B2 (en) |
| KR (1) | KR100224330B1 (en) |
| AT (1) | ATE134363T1 (en) |
| AU (1) | AU661475B2 (en) |
| CA (1) | CA2105683C (en) |
| CZ (1) | CZ282997B6 (en) |
| DE (1) | DE69208464T2 (en) |
| DK (1) | DK0588797T3 (en) |
| ES (1) | ES2084348T3 (en) |
| FI (1) | FI113167B (en) |
| GR (1) | GR3019069T3 (en) |
| HU (1) | HU215436B (en) |
| IT (1) | IT1244773B (en) |
| MX (1) | MX9201055A (en) |
| NO (1) | NO304592B1 (en) |
| PT (1) | PT100216B (en) |
| RU (1) | RU2111959C1 (en) |
| SK (1) | SK280134B6 (en) |
| WO (1) | WO1992016496A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ245989A (en) * | 1992-02-28 | 1995-02-24 | Lilly Industries Ltd | Anthraquinone derivatives and pharmaceutical compositions |
| GB9417102D0 (en) * | 1994-08-24 | 1994-10-12 | Lilly Industries Ltd | Pharmaceutical compounds |
| IT1276781B1 (en) * | 1995-06-23 | 1997-11-03 | Gentili Ist Spa | ANTHRACHINONMON - AND DISOLFON- SUBSTITUTED DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF DISEASES |
| GB2398780A (en) * | 2003-02-26 | 2004-09-01 | Arakis Ltd | 1,8-dihydroxyanthraquinone-6-carboxamide derivatives as inhibitors of T-cell proliferation for treatment of autoimmune or inflammatory conditions |
| CN102060809B (en) * | 2009-05-01 | 2015-05-20 | 常州高新技术产业开发区三维工业技术研究所有限公司 | Rhein derivatives and preparation and application thereof |
| CN102225913B (en) * | 2011-04-07 | 2013-09-04 | 栗进才 | Rheinic acid derivatives and treatment application thereof |
| RU2466134C1 (en) * | 2011-06-24 | 2012-11-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Иркутский государственный университет" | Method of obtaining cationic palladium complexes |
| CN104557603A (en) * | 2014-12-08 | 2015-04-29 | 石河子大学 | Rhein compounds, and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA761627B (en) * | 1976-03-16 | 1978-01-25 | C Friedmann | Improvements in or relating to the treatment of arthritis |
| US4966918A (en) * | 1989-01-27 | 1990-10-30 | Sloan-Kettering Institute For Cancer Research | Derivatives of chryosphanol |
-
1991
- 1991-03-12 IT ITMI910658A patent/IT1244773B/en active IP Right Grant
-
1992
- 1992-03-04 SK SK947-93A patent/SK280134B6/en unknown
- 1992-03-04 AU AU13596/92A patent/AU661475B2/en not_active Ceased
- 1992-03-04 KR KR1019930702709A patent/KR100224330B1/en not_active IP Right Cessation
- 1992-03-04 US US08/117,065 patent/US5451606A/en not_active Expired - Fee Related
- 1992-03-04 DE DE69208464T patent/DE69208464T2/en not_active Expired - Fee Related
- 1992-03-04 WO PCT/EP1992/000479 patent/WO1992016496A1/en active IP Right Grant
- 1992-03-04 RU RU93057732A patent/RU2111959C1/en not_active IP Right Cessation
- 1992-03-04 EP EP92905647A patent/EP0588797B1/en not_active Expired - Lifetime
- 1992-03-04 DK DK92905647.1T patent/DK0588797T3/en active
- 1992-03-04 HU HU9302510A patent/HU215436B/en not_active IP Right Cessation
- 1992-03-04 JP JP4505494A patent/JP2979054B2/en not_active Expired - Fee Related
- 1992-03-04 CZ CS931829A patent/CZ282997B6/en not_active IP Right Cessation
- 1992-03-04 ES ES92905647T patent/ES2084348T3/en not_active Expired - Lifetime
- 1992-03-04 CA CA002105683A patent/CA2105683C/en not_active Expired - Fee Related
- 1992-03-04 AT AT92905647T patent/ATE134363T1/en not_active IP Right Cessation
- 1992-03-09 PT PT100216A patent/PT100216B/en active IP Right Grant
- 1992-03-11 MX MX9201055A patent/MX9201055A/en not_active IP Right Cessation
-
1993
- 1993-09-08 FI FI933925A patent/FI113167B/en not_active IP Right Cessation
- 1993-09-10 NO NO933241A patent/NO304592B1/en not_active IP Right Cessation
-
1996
- 1996-02-22 GR GR960400457T patent/GR3019069T3/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3231043B2 (en) | Pharmacologically active nitrate and its preparation | |
| CA1072112A (en) | Benzylidene derivatives | |
| KR100284838B1 (en) | New arylpropion derivatives, their preparation and use as analgesics | |
| EP0318377A2 (en) | Enantiomeric derivatives of amino acids, process for their preparation and their pharmaceutical applications | |
| EP0061386B1 (en) | (2-oxo-3-tetrahydrothienylcarbamoyl)-alkylthio acids, their salts and esters, their preparation and pharmaceutical compositions containing them | |
| CA2105683C (en) | N-¬¬4,5-dihydroxy-and 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl|carbonyl|amino acids useful in the therapy of osteoarticular affections | |
| JPS6229566A (en) | Novel guanidinomthylbenzoic acid derivative | |
| WO1991016338A1 (en) | S-(lower fatty acid)-substituted glutathione derivative | |
| EP0632026B1 (en) | Alpha amino acid derivatives, a method for their preparation and pharmaceutical preparations containing them | |
| TW200407310A (en) | Compounds | |
| US4134991A (en) | Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid | |
| JPH059424B2 (en) | ||
| CA2107150C (en) | Chromenic derivatives having a triene lateral chain, process for the preparation thereof and pharmaceutical compositions containing them | |
| JPH0215048A (en) | Neopentyl ester derivative, and its production and use thereof as medicine | |
| NO174848B (en) | Analogous Process for Preparing Therapeutically Active Substitutes | |
| US20060135785A1 (en) | Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof | |
| JP3490114B2 (en) | Chondroprotectors | |
| US4116972A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
| JPH04178359A (en) | Tetracycline derivative | |
| JPS5892646A (en) | Benzylidene derivative | |
| IE60565B1 (en) | Optically active oxo-isoindolinyl derivatives | |
| JPH0454160A (en) | Tetracycline derivative | |
| CA1105053A (en) | No translation available | |
| CN113402414A (en) | Benzoic acid derivative and preparation method and pharmaceutical application thereof | |
| JPS591267B2 (en) | Thiazine derivatives and their production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |